CSL Research Acceleration Initiative
Fast-track discovery of innovative biotherapies
CSL’s Research Acceleration Initiative aims to fast track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL’s therapeutic areas.
Expressions of interest are sought from Business Development / Commercialization representatives across global research organizations that wish to participate in the 2023 CSL Research Acceleration Initiative.
Successful applicants will receive up to $200k p.a. for up to two years (max $400k funding). Interested researchers are invited to contact their Tech Transfer/Commercialization office for information session webinar links and online application instructions.
Areas of Interest for Collaboration
The 2023 Research Acceleration Initiative will focus on innovative research projects that address unmet medical needs and are aligned with CSL’s Therapeutic Areas and scientific Platforms:
Primary immune deficiency gene therapy and targets
(e.g. Primary Sjögren’s syndrome, systemic sclerosis, inflammatory idiopathic myopathies incl. dermatomyositis, autoimmune blistering diseases)
Therapeutic strategies for autoimmune diseases
• Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF family members
• B cell depletion / regulation strategies
Alternatives to plasma-derived immunoglobulin / Recombinant IVIg
Hemorrhagic and acute ischemic stroke
• Novel biologic targets/therapeutics or strategies to understand pathomechanisms
• Biomarker/Omics approaches for patient stratification and drug discovery
Acute thrombosis (venous and arterial thrombosis)
Novel therapies/approaches for targeted fibrinolysis/thrombolysis with increased efficacy and safety
Sickle cell disease
Prophylactic therapies to reduce vaso occlusive crises and chronic vasculopathy
Chronic obstructive pulmonary disease
Non-cystic fibrosis bronchiectasis
Interstitial lung diseases
Community acquired pneumonia (CAP)-associated complications
(acute respiratory distress syndrome, sepsis, acute kidney injury)
Cardiovascular & Metabolic
Severe forms of atherosclerosis
Rare lipid disorders
(e.g. homozygous familial hypercholesterolemia)
Chronic lung allograft dysfunction
Including prevention, antibody mediated rejection, tolerance, immunomodulation, biomarkers, animal models
Hematopoietic stem cell transplant (HSCT)
Treatment and prevention of acute and chronic GvHD, tolerance, immunomodulation, improving efficacy / safety of HSCT
Cardiovascular allograft vasculopathy
Treatment and animal models
Ischemia reperfusion injury
mRNA and lipid nanoparticle platform
Innovative research addressing improved delivery, formulation, stabilization (5 C / room temperature), shelf life extension and manufacturing technologies
Influenza virus antigen purity and yield enhancement
Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture
Proven adjuvant technology
Partnerships with our proprietary adjuvant MF59®
Cell & Gene Therapy
- In vivo kill switch or suicide switch
- Modulation of transgene expression in vivo
- Novel methods to select gene modified HSCs
- Novel therapeutic gene therapy targets aligned with CSL’s Therapeutic Areas
- Non viral in vivo delivery of RNPs
- Alternative mRNA delivery methods
Plasma & Recombinant Technologies
- Oral delivery of biologics
- Protein purification technologies
- Bioprocess improvements
- MDCK cell culture yield improvements
Want to learn more? Register for an information session:
Why Collaborate with CSL?
Global capabilities on your doorstep.
Work with one of the world’s leading biotech companies.
Funding for successful proposals.
Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise.
Accelerate translation of your research to deliver new therapies to patients.
CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.